Bio Sidus SA   Report issue

For profit Phase 3 Phase 4
Founded: Buenos Aires Argentina (1983)
Status: No NME R&D (1983)

Organization Overview

First Clinical Trial
2011
NCT01374373
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Bio Sidus SA

Active Ingredients

Drugs in Phase 4 Trials (2)

epoetin (Epogen) (3 trials)

teriparatide (1 trial)

Drugs in Phase 3 Trials (1)

agalsidase beta (Fabrazyme) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 4)

Fractures, Spontaneous (Phase 4)

Kidney Diseases (Phase 3)

Osteoporosis (Phase 4)

Osteoporosis, Postmenopausal (Phase 4)

Osteoporotic Fractures (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 3